Market Place
Sourcing Support
Direct Biologics Announces Publication of Survival Benefit with ExoFlo in PhII
12 Jul 2023 //
BUSINESSWIRE
Direct Biologics Announces Initiation of PI Trial for Refractory Crohn’s Disease
21 Mar 2023 //
BUSINESSWIRE
Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo
14 Mar 2023 //
BUSINESSWIRE
Direct Biologics Appoints Dr. Amy Lightner as Chief Medical Officer
15 Feb 2023 //
BUSINESSWIRE
Good Works II Acquisition Corp. & Direct Biologics Announce a Agreement
13 Oct 2022 //
BUSINESSWIRE
Good Works II Announces Letter of Intent with Direct Biologics, LLC
27 Sep 2022 //
BUSINESSWIRE
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 (ARDS) Trial
21 Apr 2022 //
PRNEWSWIRE
Enforcement Report - Week of March 16, 2022
17 Mar 2022 //
FDA
Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND
20 Jul 2021 //
PRNEWSWIRE
Direct Biologics Granted FDA Approval of Third IND Application for ExoFlo
29 Jun 2021 //
PR NEWSWIRE
Direct Biologics begins phase II for COVID-19 associated ARDS
01 Jan 2021 //
PHARMABIZ
Direct Biologic Initiates Patient Enrollment in the Phase II EXIT COVID-19 Trial
09 Sep 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.